ICD-10: C83.95

ICD-10 code C83.95 refers to Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of the inguinal region and lower limb. This classification falls under the broader category of non-Hodgkin lymphoma (NHL), which encompasses a diverse group of blood cancers that originate in the lymphatic system.

Clinical Description

Definition

Non-follicular lymphoma is characterized by the proliferation of lymphoid cells that do not form the follicular structures typical of follicular lymphoma. This type of lymphoma can manifest in various forms, including diffuse large B-cell lymphoma (DLBCL), which is the most common subtype of non-Hodgkin lymphoma. The term "unspecified" indicates that the specific subtype of non-follicular lymphoma has not been determined or documented.

Affected Areas

The lymph nodes of the inguinal region (located in the groin) and lower limb are the primary sites affected by this condition. Lymph nodes in these areas can become enlarged due to the infiltration of malignant lymphoid cells, leading to symptoms such as swelling, pain, or discomfort.

Symptoms

Patients with C83.95 may experience a range of symptoms, including:
- Lymphadenopathy: Swelling of the lymph nodes in the inguinal region and lower limbs.
- Pain or discomfort: This may occur in the affected areas due to pressure from enlarged lymph nodes.
- Systemic symptoms: These can include fever, night sweats, unexplained weight loss, and fatigue, which are common in many types of lymphoma.

Diagnosis

Diagnosis typically involves a combination of:
- Physical examination: Assessment of lymph node enlargement.
- Imaging studies: Such as CT scans or PET scans to evaluate the extent of lymphadenopathy and any involvement of other organs.
- Biopsy: A definitive diagnosis is made through the histological examination of lymph node tissue, which helps to identify the specific type of lymphoma.

Treatment

Treatment options for non-follicular lymphoma may vary based on the specific subtype, stage of the disease, and overall health of the patient. Common treatment modalities include:
- Chemotherapy: Often the first line of treatment, especially for aggressive forms like DLBCL.
- Radiation therapy: May be used in localized cases or as a palliative measure.
- Immunotherapy: Targeted therapies that harness the body’s immune system to fight cancer cells.
- Stem cell transplant: Considered in certain cases, particularly for relapsed or refractory lymphoma.

Conclusion

ICD-10 code C83.95 captures a specific diagnosis of non-follicular lymphoma affecting the lymph nodes in the inguinal region and lower limb. Understanding the clinical implications, symptoms, and treatment options is crucial for effective management of this condition. Early diagnosis and tailored treatment strategies can significantly impact patient outcomes in cases of non-Hodgkin lymphoma.

ICD-10 code C83.95 refers to Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of the inguinal region and lower limb. This classification falls under the broader category of non-Hodgkin lymphoma (NHL), which encompasses a diverse group of blood cancers that originate in the lymphatic system. Below is a detailed overview of the clinical presentation, signs, symptoms, and patient characteristics associated with this condition.

Clinical Presentation

Overview of Non-follicular Lymphoma

Non-follicular lymphoma is characterized by the proliferation of malignant lymphocytes that do not form follicular structures. This type of lymphoma can manifest in various forms, with diffuse large B-cell lymphoma (DLBCL) being one of the most common subtypes. The unspecified nature of C83.95 indicates that the specific subtype has not been determined, which can complicate diagnosis and treatment.

Affected Areas

The inguinal region and lower limbs are significant sites for lymphatic drainage, making them common areas for lymphadenopathy in cases of lymphoma. The involvement of these regions can lead to localized symptoms and systemic manifestations.

Signs and Symptoms

Common Symptoms

Patients with C83.95 may present with a variety of symptoms, including:

• Lymphadenopathy: Swelling of lymph nodes in the inguinal region and potentially in the lower limbs. This is often the most noticeable sign and can be unilateral or bilateral.
• Pain or Discomfort: Enlarged lymph nodes may cause pain or a feeling of fullness in the groin or leg area.
• Systemic Symptoms: Patients may experience systemic symptoms such as:
• Fever: Often low-grade but can be persistent.
• Night Sweats: Profuse sweating during the night, which can disrupt sleep.
• Weight Loss: Unintentional weight loss over a short period, often exceeding 10% of body weight.
• Fatigue: A general feeling of tiredness or lack of energy that is not relieved by rest.

Additional Signs

• Skin Changes: In some cases, patients may develop skin lesions or rashes, particularly if the lymphoma has a cutaneous manifestation.
• Splenomegaly or Hepatomegaly: Enlargement of the spleen or liver may occur, although these are less common in localized lymphomas.

Patient Characteristics

Demographics

• Age: Non-follicular lymphomas can occur at any age but are more prevalent in adults, particularly those over 60 years old.
• Gender: There is a slight male predominance in the incidence of non-Hodgkin lymphoma, including non-follicular types.

Risk Factors

• Immunocompromised State: Patients with weakened immune systems, such as those with HIV/AIDS or those on immunosuppressive therapy, are at higher risk.
• Previous Infections: Certain viral infections, such as Epstein-Barr virus (EBV) or hepatitis C, have been associated with an increased risk of developing lymphomas.
• Family History: A family history of lymphoma or other hematologic malignancies may increase risk.

Comorbidities

Patients may present with other health conditions that can complicate the clinical picture, such as diabetes, cardiovascular diseases, or other malignancies.

Conclusion

ICD-10 code C83.95 encompasses a complex clinical picture characterized by lymphadenopathy in the inguinal region and lower limbs, along with systemic symptoms that may significantly impact a patient's quality of life. Early recognition and diagnosis are crucial for effective management, which may include chemotherapy, radiation therapy, or targeted therapies depending on the specific subtype and stage of the lymphoma. Understanding the clinical presentation and patient characteristics associated with this condition can aid healthcare providers in delivering timely and appropriate care.

ICD-10 code C83.95 refers to "Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb." This classification falls under the broader category of non-Hodgkin lymphoma (NHL), which encompasses various types of lymphomas that do not originate from follicular (B-cell) structures.

Alternative Names and Related Terms

1. Non-Hodgkin Lymphoma (NHL): This is a general term for a diverse group of blood cancers that includes all types of lymphomas except Hodgkin's lymphoma. C83.95 specifically refers to a subtype that is non-follicular.

2. Diffuse Large B-Cell Lymphoma (DLBCL): While not synonymous with C83.95, DLBCL is a common type of non-follicular lymphoma. It is characterized by large B-cells that proliferate in a diffuse pattern.

3. Lymphoma, Non-follicular Type: This term can be used interchangeably with non-follicular lymphoma to describe lymphomas that do not exhibit follicular architecture.

4. Lymphadenopathy: This term refers to the enlargement of lymph nodes, which can be a symptom of lymphoma, including C83.95.

5. Inguinal Lymphoma: This term specifies the location of the lymphoma, indicating that it affects the lymph nodes in the inguinal region.

6. Lower Limb Lymphoma: Similar to inguinal lymphoma, this term highlights the involvement of lymph nodes in the lower limb area.

7. Unspecified Non-follicular Lymphoma: This phrase emphasizes that the specific subtype of non-follicular lymphoma is not defined, which is a key aspect of the C83.95 code.

Related ICD Codes

• C83.9: Non-follicular lymphoma, unspecified. This code is broader and does not specify the location of the lymphoma.
• C85.9: Non-Hodgkin lymphoma, unspecified. This code encompasses all non-Hodgkin lymphomas without specifying the type or location.

Conclusion

Understanding the alternative names and related terms for ICD-10 code C83.95 is crucial for accurate diagnosis, treatment planning, and coding in medical records. These terms help healthcare professionals communicate effectively about the condition and ensure appropriate management strategies are employed. If you need further details or specific information about treatment options or prognosis related to this condition, feel free to ask!

The diagnosis of Non-follicular (diffuse) lymphoma, unspecified, particularly in the context of lymph nodes of the inguinal region and lower limb, is guided by specific clinical and pathological criteria. The ICD-10 code C83.95 is used to classify this type of lymphoma, which falls under the broader category of Non-Hodgkin lymphoma (NHL). Below are the key criteria and considerations for diagnosis:

Clinical Presentation

1. Symptoms: Patients may present with symptoms such as:
   - Painless swelling of lymph nodes in the inguinal region or lower limb.
   - Systemic symptoms like fever, night sweats, and unexplained weight loss.
   - Fatigue or weakness.

2. Physical Examination: A thorough physical examination is essential to identify enlarged lymph nodes, particularly in the inguinal area and lower limbs, which may indicate lymphatic involvement.

Diagnostic Imaging

1. Imaging Studies: Imaging techniques such as:
   - Ultrasound: Useful for assessing lymph node size and characteristics.
   - CT Scans: Provide detailed images of lymph node involvement and can help in staging the disease.
   - PET Scans: May be used to evaluate metabolic activity of lymph nodes and detect any systemic involvement.

Laboratory Tests

1. Blood Tests: Routine blood tests may reveal abnormalities such as:
   - Anemia or thrombocytopenia.
   - Elevated lactate dehydrogenase (LDH) levels, which can indicate tumor burden.

2. Biopsy: A definitive diagnosis typically requires a biopsy of the affected lymph node. The biopsy can be:
   - Excisional Biopsy: Removal of an entire lymph node for histopathological examination.
   - Core Needle Biopsy: Less invasive, but may not provide sufficient tissue for diagnosis.

Histopathological Examination

1. Microscopic Analysis: The biopsy specimen is examined under a microscope to identify:
   - The presence of atypical lymphoid cells.
   - The architecture of the lymph node, which is often disrupted in diffuse lymphomas.
   - Immunophenotyping to determine the specific type of lymphoma, which is crucial for treatment planning.

2. Classification: Non-follicular lymphomas are characterized by diffuse infiltration of lymphoid tissue, and further classification may be necessary to distinguish between various subtypes, such as diffuse large B-cell lymphoma (DLBCL) or other aggressive forms.

Staging

1. Ann Arbor Staging System: This system is commonly used to stage lymphomas based on the extent of disease:
   - Stage I: Involvement of a single lymph node region.
   - Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm.
   - Stage III: Involvement of lymph node regions on both sides of the diaphragm.
   - Stage IV: Disseminated involvement of one or more extralymphatic organs.

Conclusion

The diagnosis of Non-follicular (diffuse) lymphoma, unspecified, particularly affecting the lymph nodes of the inguinal region and lower limb, involves a comprehensive approach that includes clinical evaluation, imaging studies, laboratory tests, and histopathological examination. Accurate diagnosis is crucial for determining the appropriate treatment strategy and improving patient outcomes. If you have further questions or need more specific information, feel free to ask!

Non-follicular lymphoma, particularly the subtype classified under ICD-10 code C83.95, refers to diffuse lymphoma that is unspecified and affects the lymph nodes in the inguinal region and lower limb. This type of lymphoma is part of the broader category of non-Hodgkin lymphoma (NHL), which encompasses various subtypes with distinct treatment protocols. Here, we will explore the standard treatment approaches for this condition.

Overview of Non-Follicular Lymphoma

Non-follicular lymphoma, including diffuse large B-cell lymphoma (DLBCL), is characterized by aggressive behavior and a heterogeneous nature. The treatment strategy often depends on several factors, including the specific subtype, stage of the disease, patient’s overall health, and individual preferences.

Standard Treatment Approaches

1. Chemotherapy

Chemotherapy remains the cornerstone of treatment for non-follicular lymphomas. The most commonly used regimen for DLBCL is R-CHOP, which includes:

• Rituximab: A monoclonal antibody targeting CD20 on B-cells.
• Cyclophosphamide: An alkylating agent.
• Doxorubicin (Adriamycin): An anthracycline antibiotic.
• Vincristine (Oncovin): A vinca alkaloid.
• Prednisone: A corticosteroid.

This combination is typically administered in cycles over several months, with the number of cycles depending on the response to treatment and the disease stage[1][2].

2. Radiation Therapy

Radiation therapy may be utilized in conjunction with chemotherapy, particularly for localized disease. It can be effective in targeting specific lymph node regions, such as the inguinal area, to reduce tumor burden and improve local control. This approach is often considered after chemotherapy, especially if there is residual disease[3].

3. Targeted Therapy

In cases where the lymphoma is resistant to standard chemotherapy, targeted therapies may be considered. Options include:

• Brentuximab vedotin: An antibody-drug conjugate used for certain types of lymphomas.
• Idelalisib: A PI3K inhibitor that may be used in relapsed cases.

These therapies are typically reserved for patients who have not responded to initial treatments or have relapsed after standard therapy[4].

4. Stem Cell Transplantation

For patients with high-risk or relapsed non-follicular lymphoma, autologous stem cell transplantation (ASCT) may be an option. This procedure involves harvesting the patient’s own stem cells, administering high-dose chemotherapy to eradicate the lymphoma, and then reinfusing the stem cells to restore bone marrow function. ASCT is generally considered for younger patients or those with good performance status[5].

5. Clinical Trials

Participation in clinical trials may also be an option for patients with non-follicular lymphoma. These trials often explore new therapies or combinations of existing treatments and can provide access to cutting-edge care[6].

Conclusion

The treatment of non-follicular lymphoma, particularly for cases classified under ICD-10 code C83.95, typically involves a combination of chemotherapy, radiation therapy, and potentially targeted therapies or stem cell transplantation, depending on the individual patient’s circumstances. It is crucial for patients to discuss their treatment options with a healthcare provider specializing in hematology or oncology to determine the most appropriate approach tailored to their specific condition and overall health. Regular follow-up and monitoring are essential to assess treatment response and manage any potential side effects.